Toronto, Ontario - October 17, 2012 -- Theralase Technologies Inc. (TSX-V: TLT) announced today that its Photo Dynamic Compound (PDC) technology has been proven effective in the destruction of staphylococcus aureus and its multi drug resistant strain, methicillin resistant staphylococcus aureus, also known as MRSA.
MRSA is a bacteria strain that has grown resistant to antibiotics and hence has the potential of causing invasive infections, which are extremely difficult to treat in 25% of the population infected. In 2005, the Centers for Disease Control and Prevention reported that 94,000 individuals were hospitalized as a result of MRSA infections and there were 18,650 deaths as a result, costing the US healthcare system an additional $45 billion a year.
The scientific data supporting this discovery was presented yesterday at the 9th International Symposium of Photodynamic Therapy and Photodiagnosis in Clinical Practice held in Brixen, Italy. The presentation by Dr. Lothar Lilge confirms the significance of the research conducted by Theralase's and University Health Network's (UHN) scientists.
Dr. Arkady Mandel, Chief Scientific Officer of Theralase Inc. stated that, "Theralase unveiled to the scientific community its advanced sterilization platform technology that is able to deliver an 8 log or 99.999999% kill rate, which is comparable with complete sterilisation of life threatening infectious microorganisms, such as staphylococcus aureus and MRSA. Theralase's new PDC technology would therefore be well suited to preventing hospital acquired infections, as well as infections found in nursing homes, schools or bacterial contaminations in food processing facilities. Quite simply, once MRSA bacteria have been detected, they could be quickly destroyed utilizing Theralase's patented Photo Dynamic Compounds and proprietary light sources."
Dr. Lothar Lilge, Senior Scientist, Ontario Cancer Institute / Princess Margaret Cancer Centre, UHN stated, "Theralase's PDCs in conjunction with light exposure were shown to achieve essentially complete sterilization, even at low concentrations, against staphylococcus aureus and MRSA in an in vitro laboratory setting. The effective dose of tested PDCs was not toxic for human tissues even after 4 hours of incubation demonstrating their suitability and safety to sterilization applications. As an added benefit, the Theralase PDCs maintained their sterilizing activity even in low oxygen conditions demonstrating a Type I photosensitization effect that may open up new opportunities for the safe and effective destruction of many strains of deadly organisms and tumours that thrive in low oxygen environments, such as cancer."
Dr. Arkady Mandel went on to say, "The dramatic increase of antibiotic resistance in bacteria has led me to investigate whether Theralase's PDCs would be effective in the destruction of MRSA, as an alternative to antibacterial pharmaceutical drugs. Our successes to date will allow Theralase's PDCs to be used in the future to combat difficult to heal invasive infections. The Theralase PDCs in these studies have been chosen for their low dark toxicity to human tissue and for their high cancer and bacteria targeting properties. The Theralase PDCs are extremely promising for the development of advanced disinfection and sterilization strategies for controlling and eliminating hospital and community acquired infections, such as MRSA."
Roger Dumoulin-White, President and CEO of Theralase stated, "Based on our recent successes with our PDC technology in destroying MRSA, Theralase is actively pursuing early commercialization of this technology through strategic partnerships to co-develop the technology for particular sterilization applications. As an added benefit, due to the very low concentrations of PDCs required for sterilization, the costs of administering this technology will be very cost effective. The early commercialization of our patented PDC technology with strategic partners will dramatically improve the financial revenues of the organization. These scientific studies thus highlight Theralase's commitment to advancing its exclusive patented technologies for the ultimate goal of greater commercial opportunities for the Company."
About Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase's proprietary and patented laser technology.
For further information please visit www.theralase.com, regulatory filings may be viewed by visiting www.sedar.com.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
President & Chief Executive Officer
416-447-8455 ext. 225
Chief Financial Officer
416-447-8455 ext. 224
Chief Scientific Officer
416-447-8455 ext. 242
Director of Investor Relations
416-447-8455 ext. 262
Leave a comment...